Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... Patients who have abdominal attacks of HAE can experience episodes of severe pain, diarrhea, nausea, and vomiting caused by swelling of the intestinal wall. HAE attacks that ... Patients reported C1-esterase inhibitor (C1-INH) concentrate is an effective therapy in treating acute swelling attacks at any body location for HAE, a rare and serious ...
2009 NOV 23 ... its effects on symptoms associated with IBS. The study included 155 patients with either diarrhea-predominant IBS or mixed IBS. Two dose levels were evaluated: a 250 mg dose and a 1,000 ... Lexigen Pharmaceuticals Corporation, Pharmaceutical Business, Pharmaceutical Company, Therapy, Treatment, Lexicon Pharmaceuticals Inc. This article was prepared by ...
2009 NOV 23 ... plans for an orally administered antibody therapeutic for treatment of pediatric diarrhea. The co-developed pediatric diarrhea product will initially be targeted for commercial ... Pediatrics, Politics, Technology, United Nations, Adolescence, Diarrhea, Pediatrics, Therapy, Treatment, Wellness, Mach One Corporation. This article was prepared by ...
2009 NOV 23 ... at non-myelosuppressive doses of XMT-1001. To date, XMT-1001 has not caused severe diarrhea or hemorrhagic cystitis, serious side effects associated with non-linked CPT or ... Polymer Therap, Prodrug, Radiation-Sensitizing Agent, Solid Cancers, Solid Carcinomas, Therapy, Topoisomerase, Treatment, Xenograft, Xenotransplantion, Mersana Therapeutics Inc. ...
2009 NOV 23 ... prostate, and bladder cancers." "Common side effects include leukopenia, diarrhea, stomatitis, nausea, vomiting, and alopecia. Hand-foot syndrome (HFS) is a relatively ... of TYMS gene, which is associated with up to a 2.5-fold risk of toxicity to 5-FU therapy. Hand-foot syndrome has proven to be a dose-limiting toxicity of 5-FU, especially of ...
2009 NOV 23 ... B. polyfermenticus is available in Japan and Korea to treat intestinal disorders such as diarrhea and constipation. The bacterium is quite hardy and can survive the hostile environment ... both inflammation and wound healing, and therefore it is important to apply angiogenic therapy when there is a requirement for wound healing and anti-angiogenic therapy when there is ...
2009 NOV 23 ... manner. Patients who have abdominal attacks can experience episodes of severe pain, diarrhea, nausea, and vomiting caused by swelling of the intestinal wall. Attacks that involve ... Drugs, Enzymes, Fatigue, Hereditary Angioedema, Immunology, Nausea, Pulmonology, Therapy, Treatment, CSL Behring. This article was prepared by Biotech Business Week ...
2009 NOV 16 ... first choice in veterinary testing for many costly viral diseases such as bovine viral diarrhea or bluetongue. We now also are experiencing a growing demand for modern molecular ... Antibiotic, Antimicrobial, Bacterial Infections, Diarrhea, Klebsiella pneumoniae, Therapy, Treatment, Weight Loss, QIAGEN N.V. This article was prepared by ...
2009 NOV 23 ... 254 days. Major adverse events of Grade 3 or 4 were neutropenia (27.5%), anemia (12.5%), diarrhea (2.5%) and sensory neuropathy (2.5%)," wrote W. Koizumi and colleagues, Kitasato ... M gimestat-1 M otastat potassium) monotherapy in 32 patients and S-1-based combination therapy in 5. The median number of administered courses of paclitaxel was 3.5 (1-14). The ...
2009 NOV 16 ... toxicities across all doses were nausea, fatigue, lethargy, anorexia, proteinuria, and diarrhea, with infrequent hematologic toxicities. Pharmacokinetic data indicated rapid ... solid tumors refractory to standard therapies or for which no effective standard therapy exists. In this phase 1, open-label, dose-escalation study, patients received 35 to 160 ...
2009 NOV 16 ... adverse events reported with fluconazole use were headache, gastrointestinal pain, and diarrhea. Fluconazole is less effective than terbinafine and itraconazole in the treatment of ... States, Missoula, Drugs, Fluconazole, Onychomycosis, Pharmaceuticals, Pharmacotherapy, Therapy, Treatment, University of Montana. This article was prepared by Biotech ...
2009 NOV 24 ... According to a study from Dhaka, Bangladesh, "Rotavirus is the leading cause of diarrhea-related morbidity and mortality in developing countries, including Bangladesh. The ... Pediatrics, Rotavirus Vaccine, Vaccination, Immunization, Clinical Trial Research, Therapy, Treatment, Marketing and Licensing Agreements, Vaccines, Biotechnology, ...
2009 NOV 16 ... IBS comprises the most common forms of IBS by including patients that have either diarrhea-predominant or diarrhea-constipation alternating symptoms. Based on the most current ... assessed over one month (weeks 3, 4, 5 and 6) following completion of a 14-day course of therapy (weeks 1 and 2). Consistent with the primary endpoint in each trial, the key secondary ...
2009 NOV 16 ... is approved for the treatment of patients, 12 years of age or older, with travelers' diarrhea caused by non-invasive strains of Escherichia coli. XIFAXAN (rifaximin) is a ... patients in both treatment arms - rifaximin and placebo - received concomitant lactulose therapy. A total of 336 patients, comprised of the 299 patients who completed the six-month ...
2009 NOV 23 ... 1) of the ADVENT trial, our Phase 3 trial of crofelemer for the treatment of chronic diarrhea in people living with HIV, or HIV-associated diarrhea, and initiated the final stage ... to drugs offering major advances in treatment or providing a treatment where no adequate therapy exists. We believe this designation reflects and confirms our belief that rifaximin ...
2009 NOV 16 ... six different S-1 dose levels. The dose-limiting toxicities (DLTs) were neutropenia, diarrhea, and vomiting. At dose level 5 (100 mg/m(2)), two patients experienced DLTs, while none ... Drugs, Gastroenterology, Oncology, Oxaliplatin, Pharmaceuticals, Pre-Trials Research, Therapy, Treatment. This article was prepared by Biotech Business Week editors from ...
2009 NOV 23 ... programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the ... Pharmaceuticals, Drug Resistance, Pharmaceutical Business, Pharmaceutical Company, Therapy, Treatment, Cubist Pharmaceuticals Inc. This article was prepared by ...
2009 NOV 23 ... daily doses up to 800 mg and once-daily doses of up to 200 mg for 10 days. Headache, diarrhea, abdominal pain and nausea were the most commonly encountered treatment-emergent events; ... Human Immunodeficiency Virus, Infectious Diseases, Pharmaceuticals, Pharmacokinetics, Therapy, Treatment, Virology, Tobira Therapeutics Inc. This article was prepared by ...
